NFE2L2 and multiple sclerosis: Based on a similar concept, the therapeutic potential of NRF2-HMOX1 pathway activation and CO induction has been reported in neuroinflammation [78], multiple sclerosis [79], and systemic lupus erythematosus (SLE) [80].